Andrew Pieri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Andrew Pieri has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Henry Cain
Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, UK
3 shared publications Diane Hemming
Queen Elizabeth Hospital, Gateshead, Tyne & Wear, NE9 6SX, UK
2 shared publicationsLinsley Lunt
Queen Elizabeth Hospital, Gateshead, Tyne & Wear, NE9 6SX, UK
2 shared publicationsA. Critchley
Department of Breast Surgery, Royal Victoria Infirmary, Newcastle Upon Tyne, UK
1 shared publicationAdam Critchley
1 shared publicationColm Hennessy
1 shared publication
Latest Publications
- 1 December 2017
- Published by Elsevier in The Breast
- Vol. 36, 49-53
The introduction of radioactive seed localisation improves the oncological outcome of image guided breast conservation surgery
- 1 December 2017
- Published by Elsevier in The Breast
- Vol. 36, 49-53
The introduction of radioactive seed localisation improves the oncological outcome of image guided breast conservation surgery
- 1 October 2017
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 43 (10) , 1816-1827
A systematic review of generic and breast cancer specific life expectancy models in the elderly
- 1 October 2017
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 43 (10) , 1816-1827
A systematic review of generic and breast cancer specific life expectancy models in the elderly
- 1 May 2017
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 43 (5) , S58
Outcomes following neoadjuvant chemotherapy: converting trial results into “real world” practice
- 1 May 2017
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 43 (5) , S58
Outcomes following neoadjuvant chemotherapy: converting trial results into “real world” practice
- 1 May 2017
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 43 (5) , S12
The introduction of radioactive seed localisation improves the oncological outcome of image guided breast conservation surgery
- 1 May 2017
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 43 (5) , S12
The introduction of radioactive seed localisation improves the oncological outcome of image guided breast conservation surgery
- 1 April 2017
- Published by Elsevier in The Surgeon
- Vol. 15 (2) , 59-64
Vacuum-assisted biopsy is a viable alternative to surgical biopsy in the investigation of breast lesions of uncertain malignant potential
- 1 April 2017
- Published by Elsevier in The Surgeon
- Vol. 15 (2) , 59-64
Vacuum-assisted biopsy is a viable alternative to surgical biopsy in the investigation of breast lesions of uncertain malignant potential
- 12 July 2013
- Published by Emerald Publishing in International Journal of Health Care Quality Assurance
- Vol. 26 (6) , 559-563
Temporal artery biopsy: are we doing it right?
Temporal artery biopsy (TAB) is the gold standard for diagnosing temporal arteritis; however, sensitivity is relatively poor (30-40 per cent). The British Society of Rheumatology (BSR) guidelines state two major factors that can improve sensitivity: TAB specimen size > 10mm; and pre-biopsy steroid treatment < 7 days. Owing to the low sensitivity, TA treatment is often commenced/continued despite negative histology. The purpose of this paper is to establish the extent to which TAB results influence clinical management and determine specimen adequacy regarding BSR guidelines. In total, 55 patients underwent TAB between 2009-2011. Patients' medical notes were analysed, specifically looking at biopsy specimen size, histology results and steroid therapy duration, pre- and post-biopsy. From 55 TABs, three (6 per cent) were positive, 47 (85 per cent) were negative and five (9 per cent) were "inadequate". Of those patients with negative results, 18 (46 per cent) received > six months steroid treatment. From 50 "adequate" specimens, 31 (62 per cent) were < 10mm and 11 (28 per cent) received > seven days steroid treatment pre-biopsy. Despite negative results, many patients went on to receive long-term steroids. Action must be taken to reduce false and true negative biopsies. False negatives may-be reduced by improving adherence to BSR guidance (increased specimen size and early biopsy after commencing steroids). To reduce total true-negative biopsies, the authors suggest implementing the American College of Rheumatology scoring system, designed to objectify the decision to perform TAB. This article addresses a common problem seen in most UK hospitals. There is little literature discussing a plausible solution to reducing negative biopsies.
- 12 July 2013
- Published by Emerald Publishing in International Journal of Health Care Quality Assurance
- Vol. 26 (6) , 559-563
Temporal artery biopsy: are we doing it right?
Temporal artery biopsy (TAB) is the gold standard for diagnosing temporal arteritis; however, sensitivity is relatively poor (30-40 per cent). The British Society of Rheumatology (BSR) guidelines state two major factors that can improve sensitivity: TAB specimen size > 10mm; and pre-biopsy steroid treatment < 7 days. Owing to the low sensitivity, TA treatment is often commenced/continued despite negative histology. The purpose of this paper is to establish the extent to which TAB results influence clinical management and determine specimen adequacy regarding BSR guidelines. In total, 55 patients underwent TAB between 2009-2011. Patients' medical notes were analysed, specifically looking at biopsy specimen size, histology results and steroid therapy duration, pre- and post-biopsy. From 55 TABs, three (6 per cent) were positive, 47 (85 per cent) were negative and five (9 per cent) were "inadequate". Of those patients with negative results, 18 (46 per cent) received > six months steroid treatment. From 50 "adequate" specimens, 31 (62 per cent) were < 10mm and 11 (28 per cent) received > seven days steroid treatment pre-biopsy. Despite negative results, many patients went on to receive long-term steroids. Action must be taken to reduce false and true negative biopsies. False negatives may-be reduced by improving adherence to BSR guidance (increased specimen size and early biopsy after commencing steroids). To reduce total true-negative biopsies, the authors suggest implementing the American College of Rheumatology scoring system, designed to objectify the decision to perform TAB. This article addresses a common problem seen in most UK hospitals. There is little literature discussing a plausible solution to reducing negative biopsies.